Lakefront Biotherapeutics (LKFT) Total Debt (2020)

Lakefront Biotherapeutics (LKFT) has reported Total Debt for 6 consecutive years, with $5820.2 the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Debt rose 8.93% year-over-year to $5820.2; the TTM figure through Dec 2025 stood at $5820.2 (up 8.93% YoY), while the FY2025 annual figure was $5820.2, up 8.93% from the prior year.
• Total Debt advanced to $5820.2 in Q4 2025 per LKFT's latest filing, from $5343.0 in the prior quarter.
• Across five years, Total Debt topped out at $436589.4 in Q1 2022 and bottomed at $5343.0 in Q4 2024.
• Historically, Total Debt has averaged $217151.6 across 4 years, with a median of $233370.1 in 2021.
• Annual changes were most pronounced in 2021 — Total Debt plunged 98.66% — and 2025, when it gained 8.93%.
• Lakefront Biotherapeutics' Total Debt stood at $233370.1 in 2021, then surged by 87.08% to $436589.4 in 2022, then slumped by 98.78% to $5343.0 in 2024, then climbed by 8.93% to $5820.2 in 2025.
• Business Quant data shows LKFT's Total Debt at $5820.2 in Q4 2025, $5343.0 in Q4 2024, and $436589.4 in Q1 2022.